Piribedil


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Parkinson's disease Monotherapy: 150-250 mg/day in divided doses. W/ levodopa: 80-140 mg/day. Circulatory disorders Initial: 50 mg/day. Severe: 100 mg/day in 2 divided doses.
Dosage Details
Oral
Circulatory disorders
Adult: 50 mg daily or 100 mg daily in 2 divided doses for severe cases.

Oral
Monotherapy in Parkinson's disease
Adult: Monotherapy: 150-250 mg daily in divided doses. In combination with levodopa therapy: 80-140 mg daily.
Administration
Should be taken with food. Take at the end of a main meal.
Contraindications
Hypersensitivity, CV collapse, acute myocardial infarction, uncontrolled hypertension, pregnancy.
Special Precautions
Raynaud's syndrome, history of psychosis, renal impairment. May cause hypotension in the first few days of treatment. Regular ophthalmological monitoring is recommended. Lactation.
Adverse Reactions
Nausea, vomiting, dizziness, confusion, drowsiness, hypothermia, dyskinesias, occasional changes in liver function. Raynaud's syndrome or digital vasospasm, leg cramps.
Drug Interactions
Clonidine and dopamine antagonists eg, phenothiazines and haloperidol may antagonise effects of piribedil.
Action
Description: Piribedil is a non-ergot dopamine D2 agonist that stimulates cerebral and peripheral dopamine receptors and corrects dopamine deficiency. It is used largely, as an adjunct to levodopa therapy in the treatment of Parkinson's disease.
Disclaimer: This information is independently developed by MIMS based on Piribedil from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in